ea0086p244 | Neuroendocrinology and Pituitary | SFEBES2022
Solanke Faith
, Elamin Aisha
, Newell-Price John
, Munir Alia
, Ibbotson Victoria
Introduction: In patients with neuroendocrine tumours (NETs) somatostatin analogues are used to control symptoms in patients with functioning tumours and as antiproliferative agents in those with non-functioning tumours. During COVID-19, the Sandostatin Your Choice service was terminated by Novartis, removing home care nurses from administering the analogue in patients homes. The first generic version of depot octreotide was Olatuton® produced by Teva, a...